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Abstract
Replication-competent virus vectors are attractive ther-
apeutic agents for cancer. G207, a second-generation,
( )multimutated herpes simplex virus type 1 HSV-1 , is
one such vector that is safe in primates and efficacious
against human tumors in athymic mice. Squamous cell
carcinoma is the most frequently encountered malig-
nancy of the head and neck, and the chemotherapeutic
agent cisplatin is a standard treatment for recurrent
head and neck cancer. In this study we examine the
therapeutic potential of G207, alone and in combination
with cisplatin, against squamous cell carcinoma. Hu-
man squamous cell carcinoma cell lines are sensitive to
G207 replication and cytotoxicity in vitro at a multiplic-
ity of infection of 0.01, including cisplatin sensitive
( ) ( )UMSCC-22A , moderately sensitive UMSCC-38 , and
( )weakly sensitive SQ20B cell lines. Cisplatin did not
inhibit the cytopathic effect of G207. G207 inhibited the
growth of established subcutaneous head and neck
tumors in athymic mice. The therapeutic effects of cis-
platin and G207 in vivo were independent. However, in
( )cisplatin-sensitive tumors UMSCC-38 , combination
therapy resulted in 100% cures in contrast to 42% with
G207 or 14% with cisplatin alone. We conclude that
G207 should be considered for the treatment of head
and neck cancer and that combination with chemother-
apeutic agents may improve efficacy.
Keywords: herpes simplex virus, head and neck cancer, squamous cell carci-
noma, cisplatin, gene therapy.
Introduction
Cancers of the head and neck, which are mostly located in
the oral cavity, pharynx and larynx, affect over 50,000
persons each year in the United States and cause about
[ ]14,000 deaths 1 . Squamous cell carcinoma accounts for
[ ]85%-90% of tumors classified as head and neck cancer 2 .
Surgery and radiotherapy are effective in controlling early
stages of head and neck squamous cell carcinoma
( )HNSCC , but overall survival is still poor due to the lack of
a complete response. Recurrent head and neck cancer
causes serious complications from local-regional disease.
Necrosis or ulceration of the tumor creates disabling pain,
infection, cranial nerve dysfunction, airway compromise, im-
pairment of speech, and swallowing dysfunction with dehy-
dration and malnutrition. Until recently, chemotherapy has
been used almost exclusively for palliation in relapsed head
and neck cancer but has had relatively little role in the
curative therapy of these tumors.
Cisplatin, as a single agent, is a standard therapy for
[ ]recurrent or metastatic head and neck cancer 3,4 , but is
( )more effective 70%–90% as a combination chemotherapy
[ ]in previously untreated patients 5–7 . Impressive tumor
responses to chemotherapy are often initially observed,
however, in patients who relapse after surgery and radia-
tion, the tumors are usually chemotherapy resistant. Unfor-
tunately, recurrent and metastatic disease, which generally
can only be treated with chemotherapy, affects a large and
[ ]important subset of patients 8 . Forty percent to 60% of
patient deaths are directly attributable to uncontrolled
[ ]local-regional disease 9 , and 90% of patients with distant
metastases die with uncontrolled tumor at the primary site
[ ]or in the neck 10 . Reirradiation with chemotherapy of
unresectable recurrent head and neck cancer was shown to
prolong survival compared to either modality alone, and yet
this dual modality of treatment caused over 10% mortality
[ ]11 . Thus safe, local, innovative therapies with or without
chemotherapy are needed to palliate patients who will de-
velop and die of local-regional recurrences.
We have developed an attenuated, multimutated, replica-
( )tion-competent herpes simplex virus HSV vector termed
G207, which has proved efficacious in treating human ma-
[ ]lignant tumors 12–14 . G207 has deletions at both g34.5
( )RL1 loci and an insertion of the Escherichia coli lacZ gene
( ) [ ]inactivating the ICP6 gene UL39 12 . These mutations
result in attenuated neurovirulence, temperature sensitivity,
ganciclovir hypersensitivity, and expression of an easily
( ) [ ]detectable histochemical marker b-galactosidase 12 . Cy-
topathic effect has been demonstrated in vitro in multiple
human tumor cell lines. Intraneoplastic inoculation of G207
into established subcutaneous or intracerebral tumors in
mice leads to decreased tumor growth and prolonged sur-
[ ]vival 12–14 . However, G207 is nonpathogeneic when in-
oculated intracerebrally in mice and in HSV-sensitive, non-
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[ ]human primates 12 and is currently undergoing clinical
evaluation for the treatment of recurrent malignant glioma in
a phase I trial.
(Combination therapies radiation/chemotherapy, surge-
ry/ radiation, surgery/chemotherapy, multiple chemothera-
)peutic agents, and so on. have proved to be generally
more effective than single therapeutic agents alone in the
treatment of cancer. Unfortunately, in randomized trials for
head and neck cancer, combination chemotherapy failed to
improve survival rate when compared with single agent
[ ]chemotherapy 15–18 . Recently, such combination thera-
pies have been extended to cancer gene therapy, in which
examples include replication-competent HSV q ‘‘suicide’’
[ ]gene therapy 19,20 , replication-competent adenovirus q
[ ]‘‘suicide’’ gene therapy 21 , replication-competent aden-
[ ]ovirus q chemotherapy 22 , replication-competent HSV q
[ ]cytokine immunotherapy 23,24 , replication-competent HSV
[ ]q radiation therapy 25 , and p53 gene therapy q chemo-
[ ]therapy 26,27 . In this study we show that the combination
of cisplatin with a replication-competent HSV vector, G207,
provides an additive therapeutic response that can eradi-
cate established subcutaneous human HNSSC tumors in
athymic mice.
Materials and Methods
Viruses and Cells
G207 is an HSV-1 mutant containing deletions in both
copies of the g34.5 gene and an E coli lacZ insertion
[ ] ( )inactivating the ICP6 gene 12 . G207 clinical grade was
( )obtained from NeuroVir, Inc Vancouver, BC . Titration of
virus was performed by plaque assay on African green
( )monkey kidney Vero cells. The human squamous cell
carcinoma cell lines were established in other laboratories
from tumors of the aerodigestive tract. UM-SCC 22A,
UM-SCC 38, PCI 51, and SCC-25/CP cell lines were grown
( )in Dulbecco’s modified Eagle’s medium DMEM containing
( ) ( )10% fetal calf serum FCS Hyclone, Logan, UT ; 1%
( )penicillin-streptomycin Sigma Chemical Co., St Louis, MO ;
and 1% glutamine. SQ20B was grown in DMEM containing
( )20% FCS Hyclone ; 1% MEM nonessential amino acids
( ) (Gibco PBL, Grand Island, NY ; hydrocortisone 0.4 mg/mL;
)Sigma Chemical Co ; 1% penicillin-streptomycin; and 1%
glutamine.
Cell Culture Cytotoxicity
Subconfluent monolayers of HNSSC cells in 6-well dishes
( )were infected with G207 at multiplicities of infection MOIs
( )of 0.1 and 0.01 plaque-forming units pfu per cell, whereas
( )controls were treated with phosphate-buffered saline PBS
( )with glucose and 1% heat-inactivated FCS. Viable cell
numbers were determined by counting trypan blue –
excluding cells.
For the cisplatin cytotoxicity assay, cells were plated in
( 4 )96-well dishes 10 cells per well in improved minimum
( ) ( )essential medium, Eagle’s IMEM without phenol red
and 10% FCS. Twenty four hours after plating, cells were
(treated with aqueous cisplatin cis-diamminedichlo-
[ ]roplatinum II obtained from the Georgetown University
)Hospital Pharmacy at concentrations ranging from 3.9 =
10-7 to 10-4 mol /L, and then grown in cisplatin for 4 days.
( )Figure 1. In vitro susceptibility of human head and neck squamous cell carcinoma HNSCC cell lines to G207. Subconfluent monolayers of head and
( ) ( ) ( )neck cancer cell lines PCI 51, SCC-25/CP, UMSCC-22A, UMSCC-38, and SQ20B were infected with G207 at a MOI of 0.1 left or 0.01 right and
the viable cells counted on the days indicated. The data plotted are the mean of triplicate wells.
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Figure 2. Sensitivity of HNSCC cell lines to cisplatin cytotoxicity. Cells
were plated at equal density on day 0 and treated with increasing
concentrations of cisplatin on day 1. Cell viability was determined on
day 4 by XTT assay. The IC for the most resistant cell line, SQ20B,50
was about 9 times greater than the least resistant, UMSCC- 22A.
Cell growth and viability were determined by XTT assay
( )Polysciences, Inc, Warrington, PA at an optical density of
450 nm. The cells treated with cisplatin were compared with
control cells not treated with cisplatin.
In Vitro Cytotoxicity with Cisplatin and G207
Subconfluent monolayers of SCC-25/CP HNSCC cells in
6-well dishes were infected in triplicate with G207 at a MOI
of 0.01 pfu/cell and treated with cisplatin at 0.0075 or 0.001
mmol/L or PBS. Viable cell counts were determined by
trypan blue exclusion on days 1 to 5.
Subcutaneous Tumor Model
Six-week-old female outbred athymic nu/nu mice were
(purchased from the National Cancer Institute Frederick,
)MD . All animal procedures were approved by the George-
town University Animal Care and Use Committee. For surgi-
cal procedures, each mouse was anesthetized with a 0.25
to 0.30 mL intraperitoneal injection of a solution consisting
(of 84% bacteriostatic saline; 10% sodium pentobarbital 50
)mg/mL; Abbott Laboratories, Chicago, IL ; and 6% ethyl
alcohol.
(Tumor fragments of UM-SCC 22A 3 mm = 2 mm = 2
) ( )mm or UM-SCC 38 3 mm = 3 mm = 2 mm or SQ20B
( 6)cells 2 = 10 were implanted subcutaneously in the left
( )flanks of athymic mice n s40 / tumor cell line . When the
( )subcutaneous s.c. tumors were approximately 6 mm in
( )maximal diameter approximately 14 days postimplant , mice
( )were randomly divided into two or four groups n s 7 or 8 .
Mice harboring UM-SCC 22A or UM-SCC 38 s.c. tumors
( 7were inoculated intraneoplastically with G207 10 pfu in 20
)mL or 20 mL mock extract. Mice harboring SQ20B s.c.
tumors were inoculated intraneoplastically with 10-fold less
( 6 ) (G207 10 pfu in 20 mL or 20 mL mock extract. Cisplatin 4
)mg / kg / 100mL or PBS was intraperitoneally injected for 5
consecutive days starting day 2 or 3 after G207 injection.
( )Cisplatin 20 mg / kg per mouse total will achieve maximal
[ ]antitumoral activity with minimal side effects 29 . Mice were
weighed before cisplatin or PBS treatment and twice weekly
after treatment.
Tumor growth was determined by measuring the tumor
( )volume length = width = height twice weekly. Mice were
Figure 3. Effect of cisplatin on G207 growth and cytotoxicity. A subconfluent monolayer of SCC-25 /CP cells were infected with G207 at a MOI of 0.01
or mock infected with PBS and then treated with 0.0075 or 0.001 mmol/L cisplatin or PBS. The cells were not sensitive to cisplatin at these doses and
grew to confluence in 48 hours; they remained confluent for the following 3 days. There was no significant difference in the cytopathic efficacy of G207
at either of the cisplatin concentrations.
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Figure 4. G207 inhibition of UMSCC-22A subcutaneous tumor growth. Athymic mice bearing s.c. UMSCC-22A tumors, 6 mm in maximal diameter,
( 7 ) ( ) ( )were treated with a single intraneoplastic inoculation of G207 10 pfu; n s 8 or PBS mock; n s 7 . A The tumors were measured on the days
(indicated and tumor volume determined. Mean tumor growth was significantly inhibited in the G207-treated tumors compared to the mock tumors P
) ( )F .05 from day 11 to 47 and P s .07 on day 55; Student t test . Bars are SEM. B Kaplan-Meier survival curve. There was a significant difference in
( )survival between the control and G207-treated groups P- .01; Wilcoxon test .
Figure 5. G207 inhibition of SQ20B subcutaneous tumor growth. Athymic mice bearing s.c. SQ20B tumors, 6 mm in maximum diameter, were treated
( 6 ) ( )with a single intraneoplastic inoculation of G207 10 pfu; ns 14 or PBS mock; n s 15 . Cisplatin was injected intraperitoneally 2 days later for 5
( ) ( ) ( ) ( )consecutive days 4 mg/kg/day in a subset of the G207-treated n s 7 and mock-treated animals n s 7 . A The tumors were measured on the
days indicated and tumor volume determined. Cisplatin treatment alone had no effect on tumor growth. Mean tumor growth was significantly inhibited in
( )the G207-treated tumors compared with the mock tumors P - .025; Student t test and in the G207 q cisplatin animals compared to the mock q
( )cisplatin animals P - .005; Student t test . There was no significant difference between the G207 and G207 q cisplatin groups in the mean tumor
( ) ( )growth ratio by day 26 P s .23; Student t test . Bars are SEM. B Kaplan-Meier survival curve. Treatment with G207 or G207 q cisplatin significantly
( )increased survival compared with mock or mock q cisplatin P - .005; Wilcoxon test . There was no significant difference in survival between Mock
( ) ( )and Mock q cisplatin groups P s .77; Wilcoxon test or between G207 and G207 q cisplatin groups P s .65; Wilcoxon test . All mock-treated and
mock q cisplatin– treated animals were sacrificed by days 61 and 80, respectively. On day 100, four G207- and five G207 q cisplatin– treated mice
were alive. Among these survivors, one G207 q cisplatin animal had a tumor 12 mm in maximal diameter, and the remaining had tumors smaller than
( )at the initiation of treatment - 6 mm in maximal diameter .
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sacrificed when they appeared moribund or their tumor
diameter reached 20 mm for UMSCC-38 and SQ20B tu-
mors or tumor volume reached 1000 mm3 for UMSCC-22A
tumors, and the date of sacrifice was recorded for survival
studies.
Statistical differences in growth ratio were assessed us-
ing a Student t test. Statistical analysis of Kaplan-Meier
survival curves was by Wilcoxon test.
Results
In Vitro Cytoxicity
We determined the in vitro susceptibility of human
HNSSC cells to G207 replication, spread, and cytotoxicity.
(All cell lines PCI 51, SCC-25/CP, UMSCC-22A, UMSCC-38
) ( )and SQ20B were destroyed ) 99% cytotoxicity by G207
( )infection at a MOI s 0.01 Figure 1 . UMSCC-22A and
SQ20B cells were the most sensitive and PCI-51 cells the
least sensitive to G207. The sensitivity to cisplatin va-
ried from an IC of approximately 0.001 mmol/L for UM-50
SCC-22A to 0.009 mmol/L for SQ20B, with UMSCC-38 in
( )between with an IC of 0.003 mmol/L Figure 2 . The IC50 50
was defined as the concentration of cisplatin causing a 50%
decrease in control absorbance.
Effect of Cisplatin on G207
We used the most cisplatin-resistant cell line, SCC-25/CP
[ ]30 , to determine the effect of cisplatin on G207 replica-
tion and cytotoxicity in vitro. Subconfluent monolayers of
SCC-25/CP cells were infected with G207 at a MOI s 0.01
and treated with two dilutions of cisplatin, one being the
( )highest clinically achievable 0.0075 mmol/L and the other
( )the usual clinical dosage 0.001 mmol/L . All control cells
( )not infected with G207 grew to confluency after 2 days,
irrespective of cisplatin concentration. There was no differ-
ence in the cytotoxicity of G207 with or without cisplatin
( )Figure 3 . SCC-25/CP cells were similar to UMSCC-38
( )cells in sensitivity to G207 see Figure 1; MOI 0.01 .
G207 Treatment of Subcutaneous Tumors
We first examined the in vivo efficacy of G207 against
established UMSCC-22A s.c. tumors, as these cells were
the most sensitive to G207 in vitro. When the s.c. tumors
reached 6 mm in maximal diameter, they were treated with
Figure 6. G207 q cisplatin inhibition of UMSCC-38 s.c. tumor growth. Athymic mice bearing s.c. UMSCC-38 tumors, 6 mm in maximal diameter, were
( 7 ) ( )treated with a single intraneoplastic inoculation of G207 10 pfu; ns 14 or PBS mock; ns 16 . Cisplatin was injected intraperitoneally 3 days later for
( ) ( ) ( )5 consecutive days 4 mg/kg/day in a subset of the G207-treated n s 7 and mock-treated animals n s 8 . Bars are SEM. Mock q
( )cisplatin–treated animals had a decrease in tumor growth compared with mock, although the difference was not significant P s .085; Student t test .
( )G207 or G207 q cisplatin treatment significantly inhibited tumor growth when compared with mock P - .0005; Student t test or mock q cisplatin
( ) ( )P - .005; Student t test . There was also a significant difference between G207 and G207 q cisplatin groups on day 52 P - .04; Student t test ,
( )with all tumors cured in the G207 q cisplatin group 7 /7 compared with only 3 /7 in the G207-treated group. In the Mock q cisplatin group, one tumor
regressed to a scar after cisplatin treatment.
Neoplasia v Vol. 1, No. 2, June 1999
G207 and Cisplatin Head and Neck Cancer Therapy Chahlavi et al. 167
( )a single intraneoplastic inoculation of G207 or PBS control .
( )In the control group n s 8 , tumors continued to grow
steadily for 4 more weeks. The mean tumor growth ratio
( )was significantly inhibited in the G207-treated group n s7
(compared with the control group p - 0.05 on day 47;
) ( )Student t test Figure 4 . On day 55, one control animal
was found dead with ascites and intraperitoneal metas-
tases, and on day 78, two more control animals were
sacrificed due to ascites and emaciation. Four control and
one G207-treated animal were sacrificed due to tumor bur-
( 3)den ) 1000 mm on day 78. All the remaining
( )G207-treated animals 6/7 were alive at day 100, com-
( )pared with only one control animal 1/8 . The tumors from
these surviving animals had regressed to scars or 10 to 30
mm3 necrotic masses when autopsied.
Combination Therapy of Subcutaneous Tumors
We next compared the effects of combination therapy,
G207 q cisplatin, on s.c. tumor growth of a moderately
( )cisplatin sensitive UMSCC-38 and a weakly cisplatin sen-
( )sitive SQ20B tumor. SQ20B cells were more sensitive to
( )G207 in vitro than UMSCC-38 see Figure 1 and the
SQ20B s.c. tumors were inoculated with a single low dose
( 6 )of G207 10 pfu . There was no inhibition or difference in
the mean tumor growth of SQ20B between the
(cisplatin-treated group and the control group Figure 5A;
)P s .35, Student t test . There was a significant inhibition
of tumor growth in the G207-treated group compared with
( )the control group Figure 5A; P - .025, Student t test .
However, there was no difference in the mean tumor growth
between the combination therapy group, G207 q cisplatin,
(and the G207-treated group Figure 5A; P s .2, Student t
)test . All control animals were sacrificed by day 61 and all
cisplatin-treated animals by day 80 due to tumor burden
( )and/or ulceration Figure 5B . This is in contrast to the 4 of
7 surviving G207-treated animals and 5 of 7 surviving G207
q cisplatin-treated animals at day 100, which is a statisti-
cally significant difference in survival compared with the
(control or cisplatin-treated groups Figure 5B; P - .005,
)Wilcoxon test .
UMSCC-38 cells were moderately sensitive to cisplatin in
( )vitro see Figure 2 , and UMSCC-38 s.c. tumors were simi-
( )larly moderately sensitive to cisplatin in vivo Figure 6 .
Tumor growth was inhibited by cisplatin but was not signifi-
(cantly different than the control group Figure 6; P ) .8,
)Student t test . In the cisplatin group, one tumor failed to
grow and regressed to a scar after cisplatin treatment. G207
( 7 )treatment 10 pfu , both with or without cisplatin, of estab-
lished UMSCC-38 s.c. tumors significantly inhibited growth
(when compared with the control animals Figure 6; P -
).0005, Student t test or the cisplatin-treated animals
( )Figure 6; P - .005, Student t test . There was also a
significant difference in the mean tumor growth ratio be-
(tween the G207 and G207 q cisplatin-treated groups Fig-
)ure 6; P s .04 on day 52, Student t test . In the G207 q
( )cisplatin-treated group ns7 all s.c. tumors were cured in
( )contrast to three in the G207-treated group ns7 .
The mean starting body weight of each group before
treatment was 21.0 " 0.5 g. Cisplatin treatment resulted in
( ) ( )Figure 7. Toxicity of tumor therapy. Weight of mice bearing UMSCC-38 A and SQ20B B tumors. Mice were weighed before initiation of cisplatin
treatment and at every tumor measurement after treatment. The starting mean weights were 22.0 " 0.5 g for UMSCC-38 and 20.0 " 0.5 g for SQ20B.
( )Bars are SEM. Cisplatin treatment resulted in a decrease in body weight of about 1.5 g 0.5–2.0 g or 2.5%–10% of body weight within 3 to 4 days of
treatment. By 10 to 12 days post-treatment, body weights recovered to their original weight, and by 3 weeks post-treatment body weights were equal to
those of the animals not treated with cisplatin. There was no difference in body weights between mock and G207-treated animals.
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(a drop in body weight of 0.5 to 2 g 2.5%–10% body weight
) ( )change within 3 to 4 days Figure 7 . Within 3 weeks after
treatment, body weights from all groups were about the
same, 22.5 " 0.5 g.
Discussion
We initially demonstrated that G207, with deletions at both
and g34.5 loci and lacZ insertion in the ICP6 gene, has
therapeutic potential for central nervous system tumors such
[ ] [ ]as meningioma 13 and glioma 12 . We have now ex-
panded the use of G207 to the treatment of HNSCC, which
constitute about 10% of cancers worldwide and cause ap-
[ ]proximately 5% of all cancer deaths 31 . The rational for
using this new treatment modality in head and neck cancers
)include 1 standard therapeutic intervention such as surgery,
radiation and chemotherapy continue to have a low 5-year
( ) [ ] )survival rate 8%–62% 32 ; 2 to date, no trial has demon-
strated improved survival as a consequence of adjuvant
[ ] )chemotherapy or combination chemotherapy 31 ; and 3
the location of HNSCC is easily accessible to local G207
inoculation because local invasion is the primary cause of
patient morbidity and mortality.
All human HNSCC cell lines tested were very sensitive to
G207 cytotoxicity in vitro. G207 was able to significantly
inhibit the growth of established UMSCC-22A, UMSCC-38,
and SQ20B s.c. tumors in vivo. In addition, G207 treatment
prevented metastasis in UMSCC-22A tumor-bearing ani-
mals, whereas 37% of the control-treated animals had signs
of tumor metastases. It has recently been shown that retro-
viral vector HSV-tk / GCV therapy can have a distant by-
stander effect on noninoculated human head and neck
tumors in outbred athymic mice, possibly because of the
actions of natural killer cells, monocytes, macrophages,
[ ]and/or B cells 33,34 . In patients, surgery or radiotherapy
improve local and regional control, but this has not had a
significant impact on survival because of deaths due to
[ ]metastatic disease 35,36 .
Cisplatin, a cell cycle nonspecific drug, produces pre-
[ ]dominantly intrastrand DNA cross-links 37 . Cisplatin
[ ]cross-links act as blocks to DNA replication 38,39 , with
cisplatin- resistant human cancer cells having higher levels
[ ]of replicative bypass than sensitive cells 40 . G207 causes
cell death during viral replication and generation of new
infectious virus and spreads to neighboring tumor cells to
repeat the process. In order for G207 to spread and destroy
the tumor, it must undergo extensive DNA replication and
transcription, processes that could be blocked by cisplatin. It
was, therefore, essential to determine whether G207 repli-
cation, spread, and cytotoxicity were inhibited by cisplatin.
In order to test the effect of high cisplatin doses on G207,
we used a HNSCC cell line that was relatively resistant to
cisplatin so that cytopathic effects of the drug would not
complicate the analysis. The SCC-25/CP cell line was de-
rived from SCC-25 by passage in escalating concentrations
[ ]of cisplatin 28 and is a little more resistant to cisplatin than
[ ]SQ20B 30 . Cisplatin had no effect on the cytopathic ability
of G207. It has been shown that intraperitoneal injection of
cisplatin was unable to significantly inhibit HSV-2 infection
[ ]in a mouse genital model 41 . Biochemical studies indicate
that HSV DNA helicase-primase complex in the presence of
HSV DNA binding protein ICP8 is able to bypass cisplatin
[ ]intrastrand cross-links in DNA 42 . The demonstration that
[ ]DNA damaging agents, cisplatin and cyclophosphamide 20 ,
are not inhibitory to HSV replication at doses that are toxic
to growing cells provides an additional means to preferen-
tially target tumor cells for death without affecting the on-
colytic virus.
When the combination therapy G207q cisplatin was
used in vivo, we found that it had an additive tumoricidal
effect on established UMSCC-38 s.c. tumors, which are
moderately sensitive to cisplatin, but no increased efficacy
over G207 alone against SQ20-B s.c. tumors, which are
only weakly sensitive to cisplatin. This supports the notion
that cisplatin and G207 are acting independently in this
system. G207 is effective against most human tumor cells,
irrespective of their chemotherapy or radiation sensitivity. In
addition, G207 did not increase the overall toxicity associ-
ated with cisplatin treatment, as determined by weight loss.
There was no ulceration of the skin at the site of the tumor
nor any neurological changes associated with the combina-
( )tion treatment data not shown . Combination therapies with
other oncolytic viral vectors and chemotherapy or radiation
have shown increased antitumor efficacy; the E1B-mutated
adenovirus in combination with cisplatin or 5-fluorouracil
was more effective at inhibiting human laryngeal carcinoma
[ ]xenografts than either therapy alone 22 , and radiation
therapy enhanced the antitumor activity of an attenuated,
replication-competent HSV against human glioma xenografts
[ ]25 .
These experiments demonstrated that G207 is an effec-
tive treatment for head and neck cancer, even for tumors
that are relatively cisplatin resistant, and should be consid-
ered for clinical evaluation. The combination of G207 q
cisplatin significantly improved efficacy in tumors that were
moderately sensitive to cisplatin without increasing toxicity.
It may also be worthwhile to explore such combination
therapies for other tumor types.
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